May 26, 2011
FDA Approves Generic Combivir for the U.S. Market
The U.S. Food and Drug Administration (FDA) has approved a generic version of the antiretroviral (ARV) Combivir (zidovudine plus lamivudine) for sale in the United States. Combivir is a nucleoside reverse transcriptase inhibitor (NRTI) that is used in conjunction with other ARVs to treat HIV disease.
The FDA gave the green light to the generic version by Teva Pharmaceuticals because the drug passed bioequivalence tests to ensure that it acts the same way in the body as the brand version of Combivir marketed by ViiV Healthcare.
Teva has not yet announced a price for the generic Combivir, though generic drugs are typically cheaper than the brand alternatives.
Search: Combivir, zidovudine, lamivudine, generic, Teva Pharmaceuticals, ViiV Healthcare, FDA
Scroll down to comment on this story.
Show comments (2 total)
[Go to top]